Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue: +13.4%
EPS: +241.5%
Free cash flow: +240.7%
Total debt: +51.6%

Quarter to September 2026, against a year earlier

28.21 0.06 +0.21%

Follow SUPN

Alert me

Market cap: $5.6B
P/E: 7.6×
Fwd P/E: 9.5×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 3.28
Beneish M: −1.52
Dividend safety: n/a

Overview

Indivior Pharmaceuticals Inc. (SUPN) P/S ratio

Alert me on P/S ratio

As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a P/S ratio of 2.4×. Over the past ten years it has ranged from 0.0× (June 2015) to 4.5× (June 2018); the current reading is higher than 50% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SUPN/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Indivior Pharmaceuticals Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SUPN/metrics/ps-ratio">Indivior Pharmaceuticals Inc. (SUPN) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	3.6×	162.10%
FY2024	1.4×	(28.78%)
FY2023	1.9×	(42.21%)
FY2022	3.4×	5.64%
FY2021	3.2×	91.29%
FY2020	1.7×	243.31%
FY2019	0.5×	(50.48%)
FY2018	1.0×	(73.08%)
FY2017	3.6×	50.23%
FY2016	2.4×	25.31%

Period	P/S ratio	Change
Sep 2026	3.1×	(16.01%)
Jun 2026	3.7×	25.20%
Mar 2026	2.9×	(19.06%)
Dec 2025	3.6×	41.73%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 4.5×

Ten-year median 2.4×

Current reading's percentile 47

Company	P/S ratio
AMRX AMNEAL PHARMACEUTICALS, INC. compare	2.0×
HIMS Hims & Hers Health, Inc. compare	2.2×
SUPN Indivior Pharmaceuticals Inc.	2.4×
RDY Dr. Reddy's Laboratories Ltd compare	3.6×
LNTH Lantheus Holdings, Inc. compare	4.2×
ALKS Alkermes plc compare	4.3×
KNSA Kiniksa Pharmaceuticals International, plc compare	7.3×
LQDA Liquidia Corporation compare	8.8×
AMLX Amylyx Pharmaceuticals, Inc. compare	35.4×
Drug Manufacturers Specialty & Generic industry median	2.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Indivior Pharmaceuticals Inc. (SUPN) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SUPN

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SUPN

Stockrow Weekly